{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:20:41Z","timestamp":1740126041565,"version":"3.37.3"},"reference-count":80,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T00:00:00Z","timestamp":1399680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>With anticonvulsant, anxiolytic, and analgesic properties, pregabalin has been evaluated for neuropathic pain and fibromyalgia (<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>). These chronic conditions diminish patients' quality of life and increase healthcare utilization and costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the current understanding of economic outcomes associated with pregabalin in neuropathic pain and<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using keywords related to economic outcomes and pregabalin, we systematically searched<jats:styled-content style=\"fixed-case\">MEDLINE<\/jats:styled-content>\u2010 and<jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>\u2010indexed literature and nonindexed \u201cgrey\u201d literature on neuropathic pain and<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>published from March 2001 to October 2012. Included studies reported economic findings associated with pregabalin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the past 11\u00a0years, 55 publications assessed the direct costs, resource use, or cost\u2010effectiveness of pregabalin for neuropathic pain and<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>. Studies generally lacked comparability due to heterogeneous patient populations, assumptions, time periods, and geographies. In the<jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>, following treatment initiation, pregabalin resulted in similar or higher levels of healthcare use for<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>compared with duloxetine. In contrast, medical costs for neuropathic pain did not significantly differ after initiation of pregabalin vs. duloxetine or other standard therapies in the<jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>, but in Spain and Sweden, retrospective database studies suggested that pregabalin was cost\u2010saving vs. gabapentin. Few economic analyses estimated indirect costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Neuropathic pain and<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>are associated with high healthcare resource use and costs. Economic studies of pregabalin in neuropathic pain and<jats:styled-content style=\"fixed-case\">FM<\/jats:styled-content>indicate some results favorable to other forms of care, but heterogeneity among study designs and populations hinder comparisons. Future economic analyses should aim to address data gaps regarding effects of pregabalin on productivity and resource use.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12193","type":"journal-article","created":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T06:43:14Z","timestamp":1399704194000},"page":"82-94","source":"Crossref","is-referenced-by-count":5,"title":["A Systematic Review of Pharmacoeconomic Studies for Pregabalin"],"prefix":"10.1111","volume":"15","author":[{"given":"Lindsay","family":"Parker","sequence":"first","affiliation":[{"name":"Evidera Lexington Massachusetts U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Huelin","sequence":"additional","affiliation":[{"name":"Evidera Lexington Massachusetts U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarmina","family":"Khankhel","sequence":"additional","affiliation":[{"name":"Evidera Lexington Massachusetts U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radek","family":"Wasiak","sequence":"additional","affiliation":[{"name":"Evidera Lexington Massachusetts U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Mould","sequence":"additional","affiliation":[{"name":"Pfizer Inc. New York New York U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,10]]},"reference":[{"volume-title":"Neuropathic Pain: An Overview. Molecular Biology of Pain","year":"1997","author":"Bennett GJ","key":"e_1_2_7_2_1"},{"key":"e_1_2_7_3_1","first-page":"223","article-title":"Prevalence of chronic pain in the British population: a telephone survey of 1037 households","volume":"4","author":"Bowsher D","year":"1991","journal-title":"Pain Clin"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-001-0021-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-8-27"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.04.013"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2005.01.014"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03403.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060146"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200211000-00002"},{"key":"e_1_2_7_12_1","unstructured":"European Medicines Agency.Lyrica (pregabalin). Summary of the European Public Assessment Report (EPAR) for Lyrica.EMA:London UKhttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000546\/human_med_000894.jsp&mid=WC0b01ac058001d124&murl=menus\/medicines\/medicines.jsp&jsenabled=true. (accessed August 23 2011)"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2007.12.004"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01589.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e3282effaa7"},{"key":"e_1_2_7_16_1","unstructured":"Lyrica Prescribing Information.Pfizer Pharmaceuticals LLC.http:\/\/www.fda.gov\/cder(accessed April 26 2010)"},{"key":"e_1_2_7_17_1","unstructured":"US Food and Drug Administration.FDA Approves First Drug for Treating Fibromyalgia [Press Release]. US FDA. Silver Spring MD.http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2007\/ucm108936.htm(accessed April 26 2010)"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond MF","year":"2005"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.20.5.11"},{"key":"e_1_2_7_20_1","unstructured":"ClaxtonK MartinS SoaresM et\u00a0al.Methods for the Estimation of the NICE Cost Effectiveness Threshold. Centre for Health Economics (CHE) Research Paper 81.http:\/\/www.york.ac.uk\/che\/news\/research-paper-81\/In Vol. York UK: University of York Centre for Health Economics 2013. (accessed October 5 2013)"},{"volume-title":"Choosing Interventions that are Cost Effective (WHO\u2010CHOICE): Cost Effectiveness Thresholds","author":"WHO","key":"e_1_2_7_21_1"},{"volume-title":"FDA approvals: Pregabalin for Neuropathic Pain in Spinal Injury [Press release]","author":"Medscape Education","key":"e_1_2_7_22_1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7052.275"},{"key":"e_1_2_7_24_1","unstructured":"NICE.Single Technology Appraisal: Specification for Manufacturer\/Sponsor Submission of Evidence. National Institute for health and Care Excellence (NICE). London UK.http:\/\/www.nice.org.uk\/aboutnice\/howwework\/devnicetech\/SpecificationForManufacturerSponsorSubmissionOfEvidence.jsp(accessed October 5 2013)."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2008.027"},{"key":"e_1_2_7_26_1","first-page":"120","article-title":"Cost\u2010effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico","volume":"8","author":"Arreola Ornelas H","year":"2012","journal-title":"Reumatol Clin"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)73731-1"},{"key":"e_1_2_7_28_1","first-page":"S154","article-title":"Impact of a prior authorization for pregabalin on health plan drug expenditures","volume":"16","author":"Bazalo G","year":"2010","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"A142","DOI":"10.1016\/j.jval.2012.03.766","article-title":"Budget impact and cost\u2010effectiveness of once\u2010daily gabapentin for the treatment of postherpetic neuralgia. Abstract and Poster PND7 (29665) ISPOR 17th Annual International Meeting, Washington, DC","volume":"15","author":"Becker RV","year":"2012","journal-title":"Value Health"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2012.671240"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00478.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00470.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.02.739"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00415.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.650773"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.632797"},{"key":"e_1_2_7_37_1","first-page":"S144","article-title":"Initial use of pregabalin, patterns of pain\u2010related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia","volume":"16","author":"Gore M","year":"2010","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2009.00292.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.629262"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.629263"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00450.x"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00440.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.03.555"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.7.4.327"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)73035-7"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00453.x"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.660254"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)72610-3"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.535878"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)72667-X"},{"key":"e_1_2_7_51_1","first-page":"447","article-title":"Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans","volume":"16","author":"Margolis JM","year":"2010","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_52_1","first-page":"e95","article-title":"Effects of a Medicaid prior authorization policy for pregabalin","volume":"15","author":"Margolis JM","year":"2009","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.03.775"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(11)72962-X"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00515.x"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-7"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2007.01246.x"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.2165\/0019053-200826120-00007"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.07.014"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009333017"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.08.1681"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X233151"},{"key":"e_1_2_7_63_1","first-page":"158","article-title":"Therapeutic and subtherapeutic dosing of pregabalin: medication adherence, healthcare resource utilization, and costs","volume":"4","author":"Sanchez RJ","year":"2012","journal-title":"Am J Pharm Benefits"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(11)72994-1"},{"key":"e_1_2_7_65_1","doi-asserted-by":"crossref","first-page":"A414","DOI":"10.1016\/j.jval.2011.08.995","article-title":"Pregabalin is associated with lower health care costs and less absenteeism than gabapentin when added to the treatment of neuropathic pain. Abstract and Poster PSY23 (28589) ISPOR 14th Annual European Congress, Madrid, Spain","volume":"14","author":"Sicras\u2010Mainar A","year":"2011","journal-title":"Value Health"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.11.005"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)73020-5"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.605113"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.03.049"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.03.027"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.11.017"},{"key":"e_1_2_7_72_1","first-page":"58","article-title":"An\u00e1lisis de costo\u2010efectividad de pregabalina versus gabapentin y carbamazepina en el tratamiento de dolor neurop\u00e1tico en pacientes con polineuropatia diab\u00e9tica en Colombia","volume":"3","author":"Toro W","year":"2008","journal-title":"Dolor"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.01.258"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.554807"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00412.x"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)72280-4"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.640730"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2012.03.001"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2012.01375.x"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2009.03.010"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.7.11.1581"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12193","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T15:45:04Z","timestamp":1716738304000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,10]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/papr.12193"],"URL":"https:\/\/doi.org\/10.1111\/papr.12193","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"type":"print","value":"1530-7085"},{"type":"electronic","value":"1533-2500"}],"subject":[],"published":{"date-parts":[[2014,5,10]]}}}